BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8050207)

  • 1. Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome.
    Prata MM; Nogueira AC; Pinto JR; Correia AM; Vicente O; Rodrigues MC; Miguel MJ
    Clin Nephrol; 1994 May; 41(5):277-83. PubMed ID: 8050207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias].
    Bertolami MC; Martinez TL; Faludi AA; Pinto LE; Melo RS; Bismarck ZF; Batlouni M
    Arq Bras Cardiol; 1991 May; 56(5):407-12. PubMed ID: 1823741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of simvastatin on lipoprotein (a) and lipoprotein composition in patients with nephrotic syndrome.
    Wanner C; Böhler J; Eckardt HG; Wieland H; Schollmeyer P
    Clin Nephrol; 1994 Mar; 41(3):138-43. PubMed ID: 8187355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lovastatin in the treatment of hypercholesterolemia in nephrotic syndrome due to diabetic nephropathy stage IV-V.
    Biesenbach G; Zazgornik J
    Clin Nephrol; 1992 Jun; 37(6):274-9. PubMed ID: 1638777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
    Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
    Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome.
    Kasiske BL; Velosa JA; Halstenson CE; La Belle P; Langendörfer A; Keane WF
    Am J Kidney Dis; 1990 Jan; 15(1):8-15. PubMed ID: 2294737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation.
    Hidalgo L; Zambrana JL; Blanco-Molina A; López-Granados A; Concha M; Casares J; Jiménez-Pérez J; López-Miranda J; Pérez-Jiménez F
    J Heart Lung Transplant; 1995; 14(3):461-7. PubMed ID: 7654731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
    Vega GL; Grundy SM
    Kidney Int; 1988 Jun; 33(6):1160-8. PubMed ID: 3165483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization.
    O'Connor PJ; Rush WA; Trence DL
    J Fam Pract; 1997 May; 44(5):462-7. PubMed ID: 9152263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma lipids and lipoprotein-cholesterol distribution in nephrotic syndrome patients during short term high dose steroid treatment.
    Arije A; Erasmus RT; Anjorin SA
    Cent Afr J Med; 1993 Oct; 39(10):211-5. PubMed ID: 8020077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
    Akçiçek F; Ok E; Duman S; Kürsad S; Unsal A; Alev M; Atabay G; Basçi A
    Adv Perit Dial; 1996; 12():261-5. PubMed ID: 8865916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
    Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
    Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
    Cui Y; Watson DJ; Girman CJ; Shapiro DR; Gotto AM; Hiserote P; Clearfield MB
    Am J Cardiol; 2009 Sep; 104(6):829-34. PubMed ID: 19733719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of once-daily extended-release lovastatin as compared to immediate-release lovastatin in patients with hypercholesterolemia.
    Lukacsko P; Walters EJ; Cullen EI; Niecestro R; Friedhoff LT
    Curr Med Res Opin; 2004 Jan; 20(1):13-8. PubMed ID: 14741066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact on lipoprotein profile after long-term testosterone replacement in hypogonadal men.
    Berg G; Schreier L; Geloso G; Otero P; Nagelberg A; Levalle O
    Horm Metab Res; 2002 Feb; 34(2):87-92. PubMed ID: 11972293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lovastatin efficacy and tolerance in primary hypercholesterolemia. The German Lovastatin Study Group].
    Thiery J; Basten A; Sommerburg C; Seidel D
    Dtsch Med Wochenschr; 1991 Jun; 116(23):887-94. PubMed ID: 2040207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol metabolism in glomerular cells: effect of lipoproteins from nephrotic patients.
    Wanner C; Krämer-Guth A; Nauck M; Quaschning T; Pavenstädt H; Schollmeyer P
    Miner Electrolyte Metab; 1996; 22(1-3):39-46. PubMed ID: 8676822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarketing analysis of lovastatin use in the VA Northern California System of Clinics: a retrospective, computer-based study.
    Swislocki AL; Lin K; Cogburn D; Fann KY; Khuu DT; Noth RH
    Am J Manag Care; 1997 Oct; 3(10):1537-45. PubMed ID: 10178460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of lovastatin (20-80 mg daily) on lipoprotein fractions in patients with severe primary hypercholesterolemia.
    März W; Grützmacher P; Paul D; Siekmeier R; Schoeppe W; Gross W
    Int J Clin Pharmacol Ther; 1994 Feb; 32(2):92-7. PubMed ID: 8004365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
    Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.